Quoin Pharmaceuticals Pharmaceuticals Submits Investigational New Drug Application To FDA For Phase II Trial Of Peeling Skin Syndrome Treatment QRX003

Loading news article.

Quoin Pharmaceuticals Pharmaceuticals Submits Investigational New Drug Application To FDA For Phase II Trial Of Peeling Skin Syndrome Treatment QRX003 | WAPE

Quoin Pharmaceuticals Pharmaceuticals Submits Investigational New Drug Application To FDA For Phase II Trial Of Peeling Skin Syndrome Treatment QRX003

Article summary

Related companies

Comments —